Viatris and mapi pharma announce fda acceptance of new drug application filing for ga depot for the treatment of relapsing forms of multiple sclerosis

Fda assigns pdufa target action date of march 8, 2024 new drug application supported by positive phase iii efficacy and safety clinical trial results milestone builds upon viatris' long-standing and continued commitment toward addressing the unmet needs of the ms community pittsburgh and ness ziona, israel , aug. 7, 2023 /prnewswire/ -- viatris inc. (nasdaq: vtrs), a global healthcare company, and mapi pharma ltd., a fully integrated, late-stage clinical development pharmaceutical company, today announced that the u.s. food and drug administration (fda) has accepted for review the companies' recently submitted new drug application (nda) for ga depot 40 mg.
VTRS Ratings Summary
VTRS Quant Ranking